sitagliptin

Sitagliptin (MK0431), a new oral hypoglycemic (anti-diabetic drug), is a new dipeptidyl peptidase-4 (DPP-4) inhibitor. This enzyme-inhibiting drug is used either alone or in combination with metformin or thiazolidinedione for treatment of type 2 diabetes mellitus. The drug can competitively inhibit a protein/enzyme and DPP-4, that leads to an incremental amount of active incretins (GLP-1 and GIP), the diminished amount of release of glucagon and increased release of insulin.

Sitagliptin phosphate (MK-0431 phosphate) is a dipeptidyl peptidase-4 (DPP4) inhibitor.

(S)-Sitagliptin phosphate, the less active S-enantiomer of Sitagliptin phosphate, is a high-potency inhibitor of DPP4. It exhibits an IC50 of 19 nM in Caco-2 cell extracts.

Sitagliptin N-sulfate is a phase II metabolite of the dipeptidyl peptidase 4 (DPP-4) inhibitor (-)-sitagliptin . Sitagliptin N-sulfate is formed via sulfation and has been found in rat bile following oral administration of (-)-sitagliptin.

rac-Sitagliptin-d4 HCl is a deuterated compound of rac-Sitagliptin HCl.

Sitagliptin phenylalanine hydrochloride, a dipeptidyl peptidase-4 (DPP-4) inhibitor [1], is a chemical compound utilized in medical applications.

Sitagliptin fenilalanil is a dipeptidyl aminopeptidase (DPP-4) inhibitor.

Sitagliptin Intermediate 2 is a useful organic compound that has been used in life science related research.

Sitagliptin phosphate monohydrate (MK-0431 phosphate monohydrate) is a potent DPP-IV inhibitor with an IC50 of 19 nM in Caco-2 cell extracts.

(-)-Sitagliptin carbamoyl glucuronide is a minor phase II metabolite of the dipeptidyl peptidase 4 (DPP-4) inhibitor (-)-sitagliptin . (-)-Sitagliptin carbamoyl glucuronide is formed by N-carbamoyl glucuronidation and has been found in rat and dog plasma following administration of (-)-sitagliptin.

Metformin hydrochloride mixture with sitagliptin phosphate is an AMP-activated protein kinase stimulant. It is also a CD26 antigen inhibitor, Gluconeogenesis inhibitor, and Glucose modulator.

(S, R)-LSN 3318839 is an allosteric modulator of the glucagon-like peptide-3318839 receptor (GLP-1R) that has demonstrated powerful hypoglycemic effects in animal models alone or in combination with sitagliptin.

Teneligliptin (MP-513) is a potent prolylthiazolidine-based DPP-4 inhibitor that competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50 values of approximately 1 nM.

AS2575959 is a novel GPR40 agonist, exhibiting glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion.